573 related articles for article (PubMed ID: 10441109)
21. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.
Naslafkih A; Sestier F
J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915
[TBL] [Abstract][Full Text] [Related]
22. Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
Lynn MM
Adv Nurse Pract; 2000 Jun; 8(6):36-41; quiz 42-3. PubMed ID: 15658206
[No Abstract] [Full Text] [Related]
23. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
24. [For coronary disease patients is certain: the lower the LDL the better].
MMW Fortschr Med; 2006 Jun; 148(24):6. PubMed ID: 16850797
[No Abstract] [Full Text] [Related]
25. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
26. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
27. [The role of cholesterol-lowering drugs in prevention of coronary heart disease].
Skałuba Z; Undas R
Przegl Lek; 1998; 55(7-8):382-7. PubMed ID: 10021881
[TBL] [Abstract][Full Text] [Related]
28. Clinical inquiries. What is the target for low-density lipoprotein cholesterol in patients with heart disease?
Stevermer JJ; Meadows SE
J Fam Pract; 2002 Oct; 51(10):893. PubMed ID: 12401164
[No Abstract] [Full Text] [Related]
29. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G
Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
[No Abstract] [Full Text] [Related]
30. A need to redefine the consensus on the use of statins in coronary heart disease prevention.
Fruchart JC
Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008
[No Abstract] [Full Text] [Related]
31. Cholesterol-lowering agent in men without CHD.
Millard P; Johnson KH
J Fam Pract; 1996 Mar; 42(3):223-4. PubMed ID: 8636668
[No Abstract] [Full Text] [Related]
32. [The new debate on cholesterol: is the lowest level the best?].
Olsson AG
Lakartidningen; 1999 Feb; 96(6):648-52. PubMed ID: 10087815
[No Abstract] [Full Text] [Related]
33. Hypercholesterolemia. Is lipid-lowering worthwhile for older patients?
Deedwania PC
Geriatrics; 2000 May; 55(5):22-8. PubMed ID: 10826262
[TBL] [Abstract][Full Text] [Related]
34. LDL-Cholesterol is the King.
Goumas GS
Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
[No Abstract] [Full Text] [Related]
35. [Type 2 diabetic: risk same as after infarct. With LDL not only the quantity counts].
MMW Fortschr Med; 2004 Jun; 146(24):4. PubMed ID: 15366509
[No Abstract] [Full Text] [Related]
36. Cholesterol-lowering drugs for primary prevention? The WOSCOP Study.
Muntoni S
Pharmacol Res; 1997 Mar; 35(3):169-70. PubMed ID: 9229402
[No Abstract] [Full Text] [Related]
37. [Treatment of hypercholesterolemia with enzyme inhibitors].
Valdés EF
Medicina (B Aires); 1988; 48(4):425-8. PubMed ID: 3076202
[No Abstract] [Full Text] [Related]
38. Summaries for patients. Benefits of lowering cholesterol levels in older patients.
Ann Intern Med; 2001 May; 134(10):S-4. PubMed ID: 11357858
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.
Brown WV; Bays HE; Hassman DR; McKenney J; Chitra R; Hutchinson H; Miller E;
Am Heart J; 2002 Dec; 144(6):1036-43. PubMed ID: 12486428
[TBL] [Abstract][Full Text] [Related]
40. [New statin introduction. With more power against hypercholesterolemia].
MMW Fortschr Med; 2002 Dec; 144(50):64. PubMed ID: 14610873
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
